Imedex® is an industry leader in providing certified, independent continuing medical education to health care professionals.

August 25, 2018

Dallas, Texas

Scientific Agenda

Saturday, August 25, 2018

7:45 am

Welcome and pre-activity learner survey

8:00 am

Role of diagnostic and therapeutic biomarkers in pediatric IBD

8:25 am

Debate 1
Point: Reactive therapeutic drug monitoring (TDM) is best in pediatric IBD:

Counterpoint: Proactive therapeutic drug monitoring is best in pediatric IBD:

8:55 am

Panel discussion on TDM and biomarkers

9:10 pm

Managing behavioral health in IBD

9:35 am

Transition of care from pediatrics to adults: Do's and Dont's

10:00 am

Question & answer session, post activity-learner survey

10:15 am

Break

10:35 am

Pre-activity learner survey

10:40 am

Overcoming clinical dilemmas in management of IBD during pregnancy

11:05 am

Health maintenance and vaccine needs for IBD

11:30 am

Emerging role of biosimilars in IBD

11:55 pm

Question & answer session, post-activity learner survey

12:10 pm

Lunch

1:10 pm

Pre-activity learner survey

1:15 pm

Debate 2
Point: Endoscopic remission is a gold standard with the newer biologic therapy:

Counterpoint: Clinical remission is all that matters while dealing with the new biologic therapy:

1:45 pm

Panel discussion on mucosal vs clinical remission

2:00 pm

Future IBD targets

2:25 pm

Question & answer session, post activity-learner survey

2:40 pm

Break

3:00 pm

Pre-activity learner survey

3:05 pm

Debate 3
Point: Combination therapy is necessary if you use anti-TNF:

Counterpoint: Monotherapy is necessary if you use anti-TNF:

3:35 pm

Panel discussion on combination vs monotherapy

3:50 pm

Management of acute severe ulcerative colitis

4:15 pm

Decision support tools in IBD

4:40 pm

Question & answer session, final remarks and post-activity learner survey

4:55 pm

Adjourn